cyrilzakka/clinical-trials huggingface dataset:
Bone Height and Extractions Study

A coronectomy is often chosen over complete extraction of a lower third molar when the tooth appears to be in close proximity to the inferior dental (ID) canal, as assessed on a plain radiograph or a cone beam computer tomograph (CBCT). Following a coronectomy, the roots of the third molar may migrate in a coronal direction. This effect, along with the bone-preserving technique of a coronectomy over extraction, may provide increased bone height distal to the lower second molars, when compared to extraction. Partially erupted lower third molars, specifically those with mesio-angular impactions, are commonly associated with reduced bone height distal to lower second molars, and cause damage to the periodontal support of these neighboring teeth. It is assumed that maintenance of the impacted third molars or extraction of these teeth may compromise the periodontal status of the lower second molars. This study will investigate if coronectomy improves the bone levels, and therefore the periodontal status, of lower second molars, and may propose an indication for a coronectomy regardless of the proximity of the tooth to the ID canal.

Coronectomies were first proposed as a treatment option just over thirty years ago, but there are very few long-term studies on the procedure reported in the literature. To the best of the investigator's knowledge, this will be the first randomised controlled trial comparing the bone height distal to the lower second molar following a coronectomy or extraction of the lower third molar.


Eligibility Criteria:
Inclusion Criteria:

* Patients requiring extraction of both lower third molars
* Both lower third molars to have mesio-angular impa
* ctions, as assessed by location of the contact point between the crown of the third molar and the cemento-enamel junction (CEJ) of the second molar and the angulation of the third molar
* Both lower third molars must lie above or clear of the ID canal as assessed on a plain radiograph or CBCT
* Presence of lower second molars
* Patients must be ≥18yrs old
* Patients willing to attend follow up appointments

Exclusion Criteria:

* Lower third molars with caries, periapical pathology or associated lesions such as cysts
* Patients who are immunocompromised, have a history of or due to have head and neck radiotherapy, chemotherapy, have previously been given or due to start intravenous bisphosphonates
* Smokers (\>5 cigarettes/day)
* Patients involved in current research or have recently been involved with research prior to recruitment
A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.

This study will determine the maximum tolerated dose of RO5045337 and the optimal associated 4 weekly dosing schedule of RO5045337, administered as monotherapy in patients with hematologic neoplasms. A first cohort of patients will receive the starting dose of 20mg/m2/day orally, once daily for 10 days in each 28 day cycle. Subsequent cohorts of patients will receive dose escalations, and possible changes in dosing schedule, based on tolerability and pharmacokinetic knowledge gained from prior treatment cohorts. Different formulations of RO5045337 will be tested and the food effect evaluated. The anticipated time on study treatment is until disease progression or intolerable toxicity.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients, \>=18 years of age
* Acute myeloid leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia in blast phase, refractory chronic lymphocytic leukemia/small cell lymphocytic lymphoma
* Relapsed or refractory to approved therapies, or no viable alternative therapy available
* ECOG performance status of 0-2

Exclusion Criteria:

* Patients receiving any other agent or therapy to treat their malignancy
* Pre-existing gastrointestinal disorders which may interfere with absorption of drugs
* Clinically significant cardiovascular disease
* Pregnant or lactating women
* HIV-positive patients receiving combination antiretroviral therapy
* Amendment J and onward for patients in the food effect evaluation and for all subsequent patients if dosing with a high fat/high calorie meal is found to be optimal: Patients with allergies to any ingredient in the defined liquid supplement and/or inability to tolerate a high fat/high calorie meal twice daily on scheduled RO5045337 dosing days
Odiparcil For The Prevention Of Venous Thromboembolism

Odiparcil is being studied to determine if it can prevent blood clots from forming after a total knee replacement and also to prove that odiparcil is safe.


Eligibility Criteria:
Inclusion Criteria:

* Women must be unable to have children.
* Will have a total knee replacement.

Exclusion Criteria:

* Allergic to any X-ray dye.
* Allergies or reactions to warfarin or coumadin.
* Previous VTE (venous thromboembolism) or deep vein thrombosis (DVT).
* On anticoagulation therapy.
* Renal impairment.
* Participated in any clinical trial in the past 30 days.
Pain Trajectories and Predictors After Noncardiac Surgery in Elderly Patients

This study will use group-based trajectory modeling to identify the different postoperative pain trajectory groups that exist in a mixed surgical population (non-cardiac surgery) of elderly patients during the first seven days after surgery. The aim of this study is to explore the diversity in the development of postoperative pain among elderly patients and to identify the risk factors for acute pain trajectory after surgery by investigating demographic, psychological, and clinical variables. The predictive effect of different trajectories of early postoperative acute pain on postoperative chronic pain will also be explored.


Eligibility Criteria:
Inclusion Criteria:

1. Scheduled for thoracic, urologic, gastrointestinal, gynecological, liver, biliary/pancreatic, or major orthopedic surgery under general anesthesia
2. Age ≥ 65 years
3. The American Society of Anaesthesiologists(ASA) I to III
4. Duration of hospitalization ≥ 72 hours

Exclusion Criteria:

1. Language disorder;
2. Hearing impairment;
3. Visual impairment;
4. The expected postoperative intubation time is more than 24 hours;
5. Critical events occurred during the perioperative period.
Fourth Dose of mRNA COVID-19 Vaccine in Residents of LTCFs

This study is a multi-centre, blinded, randomized controlled trial. LTCF residents ≥ 65 years who have received three doses of mRNA vaccine will be randomized to vaccination with a fourth dose of Pfizer-BioNtech mRNA- COVID-19 vaccine or to vaccination with a control (Prevnar-13 vaccine).

The primary objective of this study is to test whether vaccinating LTCF residents ≥65 years with a fourth dose of Pfizer-BioNtech mRNA- COVID-19 vaccine as compared to control (PCV13) leads to an increase in detectable neutralizing antibodies. Participants will be randomized to receive either the Pfizer COVID-19 vaccine or the Pnemoccocal Prevnar-13 vaccine at baseline after bloodwork is drawn. Another blood sample will be taken 28 days later. After completion of the study, participants in the control group (pneumococcal Prevnar-13 vaccine) will be given a fourth dose of mRNA COVID-19 vaccine and will have their blood drawn 28 days post-vaccination.

Eligibility Criteria:
Inclusion Criteria:

* LTCF residents ≥ 65 years who have received three doses of mRNA vaccine.

Exclusion Criteria:

* Immunocompromised individuals due to known or suspected immunodeficiency or due to receipt of immunosuppressive medication (e.g., steroids, biologics).
* Having had a severe adverse reaction (e.g., anaphylactic allergy) to mRNA or pneumococcal vaccine.
* Having received pneumococcal polysaccharide vaccine within 12 months.
* LTCF residents who have an interval less than 3 months from their third mRNA COVID vaccine dose.
EVALUATION for YOUNG CHILDREN with AUTISM SPECTRUM DISORDERS

Collaborative early management of children under 30 months with autism spectrum disorder and their families in an ambulatory child psychiatry unit.

Early intervention in Autism Spectrum Disorder (ASD) is now considered a priority. An approach that targets both child disorders and parental distress, and supports the skills of parents, is desirable. Yet there is no early intervention by the ASD involving parents and targeting both child functioning and parenting skills specifically.

Our objective is to evaluate quantitatively and qualitatively the collaborative family support system for ASD "Coquille". This scheme combines the development of a personalized care project based on parents' priorities, an intensive single-family parent-child follow-up and a group of multi-family therapy , over a total period of 6 months. Our main hypothesis is the significant decrease in behavioral disorders of children, evaluated by CARS, following the Coquille device. Our secondary hypotheses concern the evolution of parental dimensions following the device (sense of coherence, parental skills, parental stress, coping strategies and social support). We assume that these dimensions will change as a result of the scheme, and that they will be maintained in the medium term, six months after Coquille. A semi-structured interview will qualitatively explore the dimensions related to family resources, before and after the follow-up and in the medium term. This will also allow the mother to collect experience of the device.

Eligibility Criteria:
Inclusion Criteria for the mother and the child:

* Age 18 years and over
* French language spoken and written by the parent
* Free and informed consent form , initialled and signed by the parent
* Child under 30 months of age at time of inclusion, diagnosed with autism spectrum disorder
* Total CARS score greater than or equal to 30
* Free and informed consent form, initialled and signed by legal representatives

Exclusion Criteria for the mother only:

* Any acute, somatic or psychiatric clinical condition of the mother not compatible with therapeutic intervention.
* Current engagement in an interventional research protocol
* Mother under protection of justice, guardianship or enhanced curatorship
* Mother no longer having parental authority
Promoting Evidenced-Based Tobacco Smoking Cessation Treatment in Community Mental Health Clinics

This pilot study will examine whether an implementation intervention will improve delivery of evidence-based treatment for tobacco smoking cessation for patients in community mental health clinics.

In this pilot study, the investigators will work with community mental health clinical and pilot test an implementation intervention to improve mental health providers' delivery of evidence-based tobacco smoking cessation treatment in community mental health clinics.

Eligibility Criteria:
Inclusion Criteria:

* study population: community mental health clinic staff and providers

Exclusion Criteria:

* None
Physical Activity Intervention Trial to Mitigate Muscle Loss and Increase Muscle Strength

This intervention study will be conducted on patients included in a nationwide and prospective cohort, The Oesophageal Surgery in Cancer patients: Adaptation and Recovery study (OSCAR). The OSCAR includes patients operated on for oesophageal cancer in Sweden between 2013-2018, identified through pathology departments and included in the cohort 1 year after surgery. A comprehensive interview is conducted by a research nurse during a home visit using patient reported outcomes on several HRQOL, psychosocial, emotional and nutritional aspects. Regular follow-ups are carried out at 1½, 2, 2½, 3, 4 and 5 years postoperatively.

All patients within OSCAR are invited to the intervention trial. Half of the eligible patients will be randomised to intervention and half to standard care (control group) by means of block randomisation method. The intervention group will be encouraged to adhere to a physical activity regimen of 150 minutes of weekly minimum intensity activities and 5 simple strength training exercises twice a week as instructed by the research nurse. The control group will follow their routine daily physical activity. HRQOL measures, height and weight, body composition, muscle strength, functional mobility and strength, and dietary intake are assessed before and after the intervention. Compliance will be ensured by means of a daily physical activity dairy and a weekly follow up on telephone with all patients.


Eligibility Criteria:
Inclusion Criteria:

* All patients from the nationwide prospective cohort the Oesophageal Surgery in Cancer patients: Adaptation and Recovery study (OSCAR) with willingness to participate

Exclusion Criteria:

* Current malignancies or co-morbidities, psychological or social conditions that prevent participation
* Patients with pacemakers; cochlear or other electrical implants cannot be screened using the bio-impedance scale for safety reasons
Comparison of Post-pinal Cord Injury (SCI) Locomotor Training Techniques

Background: Body weight supported (BWS) locomotor training improves overground walking ability in individuals with motor-incomplete spinal cord injury (SCI). While there are various approaches available for locomotor training, there is no consensus regarding which of these is optimal. The purpose of this ongoing investigation is to compare outcomes associated with these different training approaches.

Subjects and Methods: Subjects with chronic motor-incomplete SCI have completed training and initial and final testing. Subjects were randomly assigned to 1 of 4 different BWS assisted-stepping groups, including: 1) treadmill training with manual assistance (TM), 2) treadmill training with stimulation (TS), 3) overground training with stimulation (OG), or 4) treadmill training with robotic assistance (LR). Prior to and following participation the investigators assessed:

* Walking-related outcome measures: overground walking speed, training speed, step length and step symmetry.
* Spinal cord reflex activity
* Electromyographic (EMG) associated with walking

Hypotheses:

In individuals with incomplete spinal cord injury (SCI):

1. A 12-week period of body weight supported treadmill training with TS will produce improvements in walking function that are significantly greater than those produced by training with TM, OG, LR.
2. TS training will be associated with greater changes to spinal reflex activity than will be observed in subjects trained with manual assistance or non-assisted stepping. Changes to spinal reflex activation will be such that this activity more closely resembles that observed in non-disabled (ND) individuals.
3. Following participation in this walking regimen, EMG activity observed during walking in all groups will be more robust, more consistent and better coordinated than EMG measures obtained prior to training.


Eligibility Criteria:
Inclusion Criteria:

* motor-incomplete spinal cord injury (AIS C or D)
* at least one year post injury
* able to step with at at least one leg
* able to stand from chair with no more than moderate assist of 1 person

Exclusion Criteria:

* unstable neurologic status
* active orthopedic problem
Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells

The aim of this prospective study is to evaluate the feasibility and efficacy of metoprolol, a beta-1 adrenergic receptor blocker, in the treatment of cytokine release syndrome (CRS) caused by chimeric antigen receptor T (CAR T) cell infusions, its effects on the serum levels of Interleukin-6 (IL-6) and other cytokines.


Eligibility Criteria:
Inclusion Criteria:

* Patients with lymphoma, leukemia or other malignant diseases who were enrolled for CAR T cell therapy.

Exclusion Criteria:

Patients with contraindications indicated in metoprolol instruction, including:

* Significant bradycardia (heart rate \< 45/min)
* Cardiogenic shock
* Severe or acute heart failure
* Poor peripheral circulation perfusion
* Grade II or III atrioventricular block
* Sick sinus syndrome
* Severe peripheral vascular disease
An Open-Label, Single and Multiple Dose Pharmacokinetic Study of 90 mg and 180 mg Doses of AZD6140 in Healthy Volunteers

This will be a single centre study conducted at the 3rd hospital affiliated to Peking University. Approximately 24 healthy Chinese volunteers, male and female, will be recruited to obtain at least 20 evaluable volunteers. The primary objective of this study is to characterize the pharmacokinetics of AZD6140 and its active metabolite AR-C124910XX after single and multiple (twice daily) doses of AZD6140 90 mg and 180 mg in healthy Chinese volunteers. The secondary objective of this study is to determine the safety and tolerability of single and multiple (twice daily) 90 mg and 180 mg doses of AZD6140 by physical examination, clinical laboratory tests, vital signs, and collection of adverse events in healthy Chinese volunteers.


Eligibility Criteria:
Inclusion Criteria:

* Chinese ethnicity defined as having both parents and 4 grandparents who are Chinese
* Have a normal Body size and weigh at least 50 kg

Exclusion Criteria:

* History of diseases or other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs determined by the investigator
* Current and/or past history of intolerance or hypersensitivity to drugs with a similar chemical structure or mechanism of action to AZD6140 or any ingredient in its formulation
* Symptoms of any clinically significant illness within 2 weeks of screening
* A personal or family history of bleeding diatheses or a reasonable suspicion of vascular abnormalities including aneurysms
Re-Read Study to Compare the Brain Uptake of [18F]Flutemetamol With Brain Neuritic Plaque Density Determined Postmortem

Data from subjects who had previously been dosed with Flutemetamol (18F) Injection and imaged in Study GE-067-007, and who died on or before 10 June 2013, will be analyzed. The PET brain images previously obtained in Study GE-067-007 will be interpreted visually in randomized by 5 independent readers who are blinded to all other subject information, and the images will be classified as abnormal (positive for abnormal neuritic plaque density) or normal (negative for abnormal neuritic plaque density). The numbers of images in each category will be used to calculate sensitivity and specificity.


Eligibility Criteria:
Inclusion Criteria:

* The subject was enrolled in prior Study GE067-007.
* The subject died on or before 10 June 2013.
* The subject's brain is judged to be of suitable quality for analysis, including all regions necessary for analysis.

Exclusion Criteria:

* Not Applicable
Research and System Development on Functional 3D Optical Tomography for Skin Cell Imaging

The investigators will obtain human skin specimen (sized approximately 1 cm x 1 cm) for dermatological surgical patients in National Taiwan University Hospital, after informed consent was obtained. Human skin keratinocytes, fibroblasts, and melanocytes will be cultured from the human skin specimen. The three dimensional images of these cultured cells will be observed by a ultra-high resolution 3-dimensional optical coherence tomography.

The investigators will obtain human skin specimen (sized approximately 1 cm x 1 cm) for dermatological surgical patients in National Taiwan University Hospital, after informed consent was obtained. Human skin keratinocytes, fibroblasts, and melanocytes will be cultured from the human skin specimen. The three dimensional images of these cultured cells will be observed by a ultra-high resolution 3-dimensional optical coherence tomography.

Eligibility Criteria:
Inclusion Criteria:

* Aged between 20 to 100.
* People who received benign skin tumor removal in dermatological surgical unit. OR
* People who received skin grafts (full thickness or split thickness) for reconstruction of surgical wounds after removing malignant skin cancer.

Exclusion Criteria:

* Age less than 20 years old,
* Psychiatric patients,
* Pregnant women.
Novel VR Intervention for Use in Psychiatric Inpatient Wards

The current study aims to examine the feasibility and acceptability of a VR app for use on inpatient psychiatric wards. The study will be completed in two stages.

Stage One is a co-design stage. A virtual reality hypnotherapy app that has been developed in collaboration with the company Phase Space, will be trialled with psychiatric inpatients. 16 patients and six staff members will be recruited at this stage. The first eight patients will test the headset and provide feedback. Based on this, the app will be modified by Phase Space and then trialled by an additional eight patients. Concurrently with the recruitment of the 16 patients, six staff members from the ward will be recruited to complete an interview about the feasibility and use of virtual reality headsets on the ward. The total feedback will be taken back to Phase Space who will further modify the app to then be implemented in the pilot stage.

Stage Two is the Pilot stage. The virtual reality app will be piloted on fifteen inpatient participants. The full design of the pilot stage will be driven by the feedback given in Stage one. Participants will complete baseline questionnaires before the use of the headset, which will then be repeated when they have finished trialling the software. The measures will include a demographics questionnaire, as well as questionnaires regarding stress and anxiety, as well as other psychiatric symptoms. Patient participants will also be asked to complete an interview after they have finished participation to provide feedback on the use of the virtual reality software. A semi-structured questionnaire will be completed with six staff participants, where they will be asked to report any observations they made regarding those who used the virtual reality headset, as well as any additional feedback they have regarding the implementation of the headsets on inpatient wards.


Eligibility Criteria:
Inclusion Criteria:

* Current inpatient or staff member on an inpatient psychiatric ward
* Capacity to consent

Exclusion Criteria:

* Lacking capacity to provide consent
* History of seizures
* Has a pacemaker
Chinese Medicine WT for Spinocerebellar Ataxia Type 3

Spinocerebellar ataxia type 3 (SCA3) is one of autosomal dominant hereditary ataxias. Standing imbalance, unsteady gait, dysmetria, fatigue, and depression would occur gradually. There are no effective treatment or palliative methods for patients in the present days. However, low-dose growth hormone, or its downstream product, insulin-like growth factor I (IGF-1), may deter the progress of SCA3 in transgenic mice. The main bioactive constituent among the Chinese medicine WT possesses neuroprotective function against glutamate-induced toxicity, which is one major pathology of SCA3. It promotes neurogenesis, and increases the protein expression of IGF-1 in ischemic brains of rats. Thus, we designed a randomized, double-blind trial for patients with SCA3, if WT is a possible neuroprotective medicine.

All the subjects will be recruited from Changhua Christian Hospital. Diagnosis is confirmed by gene test and magnetic resonance image by a neurologist. They will be assigned in random and double blind, prescribed with 3 grams concentrated powder of WT or placebo, twice a day, for 12 weeks. After the washout period of 4 weeks, there will be a crossover of placebo or WT for another 12 weeks. After that, another 4-week rest will be followed by the end of trial. Check items in five check points include: 1. Blood examination (serum IGF-1, Neurofilament light chain, mitochondria copy number, 8_OHdG, delta-Ct), 2.Neurological exam (Scale for the Assessment and Rating of Ataxia), 3. Questionnaires (Modified Fatigue Impact Scale, Epworth Sleepiness Scale), 4. Handgrip strength test (which is correlated to IGF-1 value in elderly), and 5. serum metabolites, . All the data will be disclosed after the end of trial. Paired-T test or Wilcoxon Ranked Sign Test will be operated in SPSS.


Eligibility Criteria:
Inclusion Criteria:

* diagnosed as Spinocerebellar Ataxia type 3

Exclusion Criteria:

* 1. using other Chinese medicine or herbal medicine 2. allergic to Chinese medicine or herbal medicine 3. pregnancy or breast feeding 4. with other major diseases, such as cancer, stroke, heart failure, or renal failure